4 research outputs found

    Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

    Get PDF
    Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

    MaterialSample and its Properties

    No full text
    The Biodiversity Information Standards (TDWG) Material Sample Task Group*1 kicked off in the third quarter of 2021. The group’s initial focus was to1) achieve a clear conceptual delineation between the terms MaterialSample, PreservedSpecimen, LivingSpecimen, and FossilSpecimen (the terms used in basisOfRecord in the current DwC-A provided to the Integrated Publishing Toolkit (IPT) for describing physical material)2) define the conceptual relationship between these terms and the term Organism3) consider the possible implications of the activities towards the diversification of the Global Biodiversity Information Facility (GBIF) data model*2 and what standards already exist that should inform our work.Based on this conceptual work, the group is now developing a concrete proposal for a clarification of a MaterialSample class with its own properties. Our presentation will provide a brief review of the task group's progress and our thoughts about what comes next
    corecore